Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TROP2-MMAE protodrug
- Development stage
- Preclinical
- Lead developer
- Shasqi
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous, Intratumoral
01
Overview
**TROP2-MMAE protodrug** is a preclinical, click-activated cancer therapeutic system developed by Shasqi for **TROP2-expressing solid tumors**. The system comprises the TROP2-binding Fab activator SQT02, which carries tetrazine groups, and the separately administered MMAE protodrug SQP22, in which monomethyl auristatin E is attenuated and linked to trans-cyclooctene. Following tumor localization of the TROP2-directed activator, a tetrazine-trans-cyclooctene click reaction releases active MMAE locally, enabling microtubule-directed cytotoxicity while aiming to reduce systemic exposure relative to conventional antibody-drug conjugates.
- Other names
- TROP2-monomethyl auristatin E protodrugTROP-2-monomethyl auristatin E protodrugTROP 2-monomethyl auristatin E protodrug
02
Targets
TACSTD2 (Tumor-associated calcium signal transducer 2)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on TROP2-MMAE protodrug.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TROP2-MMAE protodrug.